MX2023001385A - Metodos de tratamiento usando furosemida. - Google Patents

Metodos de tratamiento usando furosemida.

Info

Publication number
MX2023001385A
MX2023001385A MX2023001385A MX2023001385A MX2023001385A MX 2023001385 A MX2023001385 A MX 2023001385A MX 2023001385 A MX2023001385 A MX 2023001385A MX 2023001385 A MX2023001385 A MX 2023001385A MX 2023001385 A MX2023001385 A MX 2023001385A
Authority
MX
Mexico
Prior art keywords
methods
furosemide
treatment
patient
edema
Prior art date
Application number
MX2023001385A
Other languages
English (en)
Spanish (es)
Inventor
John F Mohr
John Tucker
Michael Hassman
Erik Mark Pecorelli
Original Assignee
Scpharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scpharmaceuticals Inc filed Critical Scpharmaceuticals Inc
Publication of MX2023001385A publication Critical patent/MX2023001385A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/1468—Containers characterised by specific material properties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
MX2023001385A 2020-08-05 2021-08-05 Metodos de tratamiento usando furosemida. MX2023001385A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063061518P 2020-08-05 2020-08-05
PCT/US2021/044723 WO2022031959A1 (en) 2020-08-05 2021-08-05 Methods of treatment using furosemide

Publications (1)

Publication Number Publication Date
MX2023001385A true MX2023001385A (es) 2023-03-03

Family

ID=77774970

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023001385A MX2023001385A (es) 2020-08-05 2021-08-05 Metodos de tratamiento usando furosemida.

Country Status (9)

Country Link
US (1) US20230270759A1 (https=)
EP (2) EP4192473B1 (https=)
JP (1) JP7844438B2 (https=)
CN (1) CN116322704A (https=)
AU (1) AU2021320308A1 (https=)
CA (1) CA3190585A1 (https=)
IL (1) IL300152A (https=)
MX (1) MX2023001385A (https=)
WO (1) WO2022031959A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024512650A (ja) * 2021-04-02 2024-03-19 エスシーファーマシューティカルズ インコーポレイテッド フロセミドの皮下注入
EP4648761A1 (en) * 2023-01-09 2025-11-19 scPharmaceuticals Inc. Methods of treatment using loop diuretics

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6595961B2 (en) * 2001-04-16 2003-07-22 Becton, Dickinson And Company Sterilizable transfer or storage device for medicaments, drugs and vaccines
PT2981258T (pt) * 2013-04-05 2020-10-19 Scpharmaceuticals Inc Formulações farmacêuticas para administração subcutânea de furosemida
ES3041602T3 (en) * 2018-12-10 2025-11-13 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof

Also Published As

Publication number Publication date
EP4192473A1 (en) 2023-06-14
CN116322704A (zh) 2023-06-23
EP4681736A2 (en) 2026-01-21
IL300152A (en) 2023-03-01
JP2023536730A (ja) 2023-08-29
EP4681736A3 (en) 2026-03-25
US20230270759A1 (en) 2023-08-31
EP4192473B1 (en) 2025-12-03
CA3190585A1 (en) 2022-02-10
JP7844438B2 (ja) 2026-04-13
AU2021320308A1 (en) 2023-03-02
WO2022031959A1 (en) 2022-02-10

Similar Documents

Publication Publication Date Title
MX2023001385A (es) Metodos de tratamiento usando furosemida.
KR101900520B1 (ko) 복합 조성물
NZ601704A (en) Drug delivery system for dosage control having a pump and a controller
EP4272818A3 (en) Thrombolytic agent for the treatment of thromboembolism
Fu et al. Activation of cannabinoid CB2 receptors reduces hyperalgesia in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis
Zed et al. Continuous intrathecal pump infusion of baclofen with antibiotic drugs for treatment of pump-associated meningitis: Case report
Mameli et al. Bromelain: An overview of applications in medicine and dentistry
JOP20240112A1 (ar) طريقة علاج الضمور الجغرافي باستخدام ناقل العلاج الجيني الذي يعبر عن cd59 القابل للذوبان
MX379191B (es) Nuevo uso de clorhidrato de landiolol en el tratamiento a largo plazo de taquiarritmias e hipertension.
PH12021551811A1 (en) Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same
Carey Incorrect reconstitution of incobotulinumtoxinA leads to loss of neurotoxin
MX2022007305A (es) Mejoras en la administracion sin aguja.
MX2019008076A (es) Regimen terapeutico para el tratamiento de fabry usando alfa-galactosidasa estabilizada.
MA58093B1 (fr) Nouveaux analogues d'insuline et leurs utilisations
AU2019226830A1 (en) Eye drops in form of solution comprising benzopyran derivative or pharmaceutically acceptable salt thereof
RU2758124C1 (ru) Устройство для внутривенных инфузий при озонотерапии
RU2014154396A (ru) Жидкое лекарственное средство, содержащее растворенный в нем оксид углерода, и терапевтический способ его применения
MX2021013930A (es) Composiciones y metodos para tratar presbicia.
Arcinue et al. Corticosteroids in uveitis
RU2391100C1 (ru) Способ лечения больных грибковыми заболеваниями ногтей
Fursova et al. New options determining the success of treatment for neovascular age-related macular degeneration
RU2233664C2 (ru) Способ лечения красного плоского лишая
EA201590323A1 (ru) Способ введения активных веществ в головной мозг
MX2025013695A (es) Método para administrar un modulador dirigido al receptor 1 de esfingosina-1-fosfato y receptor 4 de esfingosina-1-fosfato (s1pr1 y s1pr4)
EA200802421A1 (ru) Способ лечения эндометриоза